In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), the authors observed, as a prespecified safety analysis, a dose-dependent decrease in overall cancer mortality and in the incidence of non-small-cell lung cancer (NSCLC) in patients treated with an anti-IL-1β antibody [4]. Here, IL1B is linked to non-small cell lung carcinoma.